NGM Biopharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGM research report →
Companywww.ngmbio.com
NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH.
- CEO
- David J. Woodhouse
- IPO
- 2019
- Employees
- 138
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $128.53M
- P/E
- -0.89
- P/S
- 29.10
- P/B
- 0.85
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 49.72%
- Op Margin
- -3317.79%
- Net Margin
- -3223.34%
- ROE
- -69.76%
- ROIC
- -98.49%
Growth & Income
- Revenue
- $4.42M · -92.02%
- Net Income
- $-142,375,000 · 10.50%
- EPS
- $-1.73 · 13.07%
- Op Income
- $-146,547,000
- FCF YoY
- 8.78%
Performance & Tape
- 52W High
- $4.69
- 52W Low
- $0.60
- 50D MA
- $1.55
- 200D MA
- $1.49
- Beta
- 1.26
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on NGM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 5, 24 | TCG Opportunity III GP, LLC | other | 1,000 |
| Apr 5, 24 | TCG Opportunity III GP, LLC | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP L P | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP L P | sell | 44,000 |
| Apr 5, 24 | GOEDDEL DAVID V | other | 1,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 100,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 24,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 19,619 |
Our NGM Coverage
We haven't published any research on NGM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NGM Report →